Skip to content

Telix Pharmaceuticals

US · TLX #2345 by market cap Listed 2024
8.37 -0.34 -3.90%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 7 in the most recent period (2026/Q3).
  • Total institutional ownership rose 1.2 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
48.19% +1.25pp
Institutions
152 +7
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund26.45%
Public Company15.55%
Individual/Insider8.19%
Government Pension Fund2.26%
VC/PE Fund1.47%
Sovereign Wealth Fund1.35%
Private Company0.98%
Hedge Fund0.13%
Other43.63%

Top holders as of 2026-07-21

JPMorgan Chase & Co. 8.96% · 30.44M sh
State Street Global Advisors 8.06% · 27.38M sh
Andreas Kluge 6.67% · 22.68M sh
Christian Behrenbruch 6.43% · 21.84M sh
Challenger Limited 4.98% · 16.91M sh
Citigroup Inc. 3.35% · 11.39M sh
Grand Pharmaceutical Group Limited 3.22% · 10.95M sh
Vanguard Capital Management, LLC 3.14% · 10.67M sh
Australian Super 2.26% · 7.69M sh
Vanguard Investments Australia Limited 1.92% · 6.52M sh
BlackRock 1.82% · 6.19M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

17 filings tracked · 3 buys · 0 sells

NameRoleStake
Christian Behrenbruch Co-Founder, MD, Group CEO & Executive Director 6.43%
Mark Nelson Independent Non-Executive Director 1.07%
Jann Skinner Independent Non-Executive Director 0.18%
David Cade Group Chief Medical Officer 0.11%
Darren Patti Group Chief Operating Officer 0.01%
Darren Smith Group Chief Financial Officer 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-06 Darren Smith Group Chief Financial Officer Private Acquisition +2,071 $9.66
2026-04-28 Christian Behrenbruch Co-Founder, MD, Group CEO & Executive Director Open Market Acquisition +67,935 $14.48–14.87
2026-03-28 Darren Smith Group Chief Financial Officer Derivative Exercise and Retained +1,111 --
2026-03-17 David Cade Group Chief Medical Officer Initial Statement of Beneficial 0 --
2026-03-17 Darren Smith Group Chief Financial Officer Initial Statement of Beneficial 0 --
2026-03-17 Mark Nelson Independent Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Christian Behrenbruch Co-Founder, MD, Group CEO & Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Jann Skinner Independent Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Darren Patti Group Chief Operating Officer Initial Statement of Beneficial 0 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Telix Pharmaceuticals discussion 0 comments

Add a comment